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anta Rosa, California; Elyria, Ohio; Indianapolis, Indiana; and Takoma Park, Baltimore, and Towson, Maryland
OBJECTIVES This trial examined the relative clinical efficacy, angiographic outcomes, and safety of
zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer versus
sirolimus-eluting stents (SES).
BACKGROUND Whether a cobalt-based alloy stent coated with the novel antiproliferative agent, zotarolimus,
and a phosphorylcholine polymer may provide similar angiographic and clinical benefit
compared with SES is undetermined.
METHODS A prospective, multicenter, 3:1 randomized trial was conducted to evaluate the safety and
efficacy of ZES (n  323) relative to SES (n  113) in 436 patients undergoing elective
percutaneous revascularization of de novo native coronary lesions with reference vessel
diameters between 2.5 mm and 3.5 mm and lesion length 14 mm and 27 mm. The
primary end point was 8-month angiographic in-segment late lumen loss.
RESULTS Angiographic in-segment late lumen loss was significantly higher among patients treated with
ZES compared with SES (0.34  0.44 mm vs. 0.13  0.32 mm, respectively; p  0.001).
In-hospital major adverse cardiac events were significantly lower among patients treated with
ZES (0.6% vs. 3.5%, p  0.04). In-segment binary angiographic restenosis was also higher
in the ZES cohort (11.7% vs. 4.3%, p  0.04). Total (clinically and non-clinically driven)
target lesion revascularization rates at 9 months were 9.8% and 3.5% for the ZES and SES
groups, respectively (p  0.04). However, neither clinically driven target lesion revascular-
ization (6.3% zotarolimus vs. 3.5% sirolimus, p  0.34) nor target vessel failure (12.0%
zotarolimus vs. 11.5% sirolimus, p  1.0) differed significantly.
CONCLUSIONS Compared with SES, treatment with a phosphorylcholine polymer-based ZES is associated with
significantly higher late lumen loss and binary restenosis at 8-month angiographic follow-up.
(The Endeavor III CR; http://clinicaltrials.gov/ct/show/NCT00265668?order1?) (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.035Coll Cardiol 2006;48:2440–7) © 2006 by the American College of Cardiology Foundation
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oompared with bare metal coronary stents, the beneficial
reatment with drug-eluting stents to avoid restenosis and
he need for repeat revascularization has been consistently
emonstrated in systematic, randomized clinical trials (1–8)
nd observational studies (9–11) that have included both
elected and broad patient populations with varying clinical
nd angiographic characteristics. Because of their efficacy in
imiting neointimal hyperplasia after percutaneous coronary
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alo Alto, California; ¶Medtronic, Inc., Santa Rosa, California; #North Ohio Heart
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aryland. Study support provided by Medtronic Vascular, Inc. Santa Rosa, California.P
Manuscript received by March 24, 2006; revised manuscript received August 7,
006, accepted August 7, 2006.evascularization, drug-eluting stents have become routine
herapy in clinical practice, and currently available
aclitaxel- eluting stents and sirolimus-eluting stents (SES)
ave become the comparative standard for evaluation of
ovel anti-proliferative therapies and stent technologies.
Whether safety, clinical efficacy, and angiographic out-
omes are similar between differing drug-eluting stents has
nly been recently examined (12–18). An important emerg-
ng controversy in clinical trials comparing drug-eluting
tent therapies has been the relationship of clinical end
oints such as target lesion revascularization or target vessel
ailure (generally considered the “gold standards” for assess-
ng safety and efficacy) and surrogate angiographic end
oints such as late lumen loss, which measure more precisely
he biological effects of these novel anti-restenosis therapies
n intimal hyperplasia (19,20).
Zotarolimus (ABT-578, Abbott Pharmaceuticals, Abbottark, Illinois) is a novel pharmacologic therapy with both
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December 19, 2006:2440–7 Zotarolimus-Eluting Stentsnti-proliferative and anti-inflammatory effects. A tetrazole-
ontaining macrocyclic immunosuppressant, zotarolimus
hares structural homology and biological activity with the
nti-restenotic agent sirolimus. Recently, in a randomized
rial comparing coronary revascularization with zotarolimus-
luting (ZES) and bare metal stents, treatment with ZES
as associated with significant reductions in angiographic
estenosis and repeat target lesion revascularization (8).
espite this marked benefit relative to conventional bare
etal stents, the comparative efficacy between ZES and
ther effective drug-eluting stents, such as SES, is undeter-
ined. We therefore performed a randomized, multicenter
rial to examine the relative safety, clinical efficacy, and
ngiographic outcomes of a phosphorylcholine polymer-
ased coronary stent eluting zotarolimus versus sirolimus in
atients with native coronary lesions.
ETHODS
rial overview and study population. The ENDEAVOR
II (A Randomized Controlled Trial of the Medtronic
ndeavor Drug [ABT-578] Eluting Coronary Stent System
ersus the Cypher Sirolimus-Eluting Coronary Stent Sys-
em in De Novo Native Coronary Artery Lesions) trial was
prospective, randomized, single-blinded multicenter trial
omparing ZES and SES in elective percutaneous coronary
evascularization at 29 hospitals in the U.S. Individuals
ligible for enrollment were consecutive patients age 18
ears or older with symptomatic ischemic heart disease due
o de novo stenotic lesions (50% angiographic diameter
tenosis by visual estimate) in native coronary arteries.
ngiographic inclusion criteria were a reference vessel
iameter between 2.5 mm and 3.5 mm and lesion length
14 mm and 27 mm. Patients were excluded if they
xperienced recent (72 h) myocardial infarction, under-
ent prior stent placement within the target vessel or any
ther vessel within 30 days of the index procedure, or had
ny general contraindication to the revascularization proce-
ure and routine pharmacologic therapies. Principal angio-
raphic exclusion criteria were a left ventricular ejection
raction30%, stenosis40% elsewhere in the target vessel
other than the target lesion), involvement of a sidebranch
2.0 mm in diameter, unprotected left main coronary
isease, chronic total occlusions, and Thrombolysis In
yocardial Infarction flow grade 2 in the treatment
essel. The study was approved by the institutional review
Abbreviations and Acronyms
CK  creatine kinase
IVUS  intravascular ultrasound
MACE  major adverse cardiac events
MLD  minimal lumen diameter
SES  sirolimus-eluting stent
ZES  zotarolimus-eluting stentoard at each enrolling site, and consecutive, eligible pa- cients signed written informed consent before the interven-
ional procedure.
evice description. The Endeavor drug-eluting coronary
tent (Medtronic Vascular, Inc., Santa Rosa, California) is a
obalt-based alloy stent with a phosphorylcholine polymer
21) and zotarolimus dose concentration of 10 g/mm stent
ength. In a porcine coronary model, stents coated with a
hosphorylcholine polymer and zotarolimus were associated
ith significant reductions in neointimal area and percent
rea stenosis (22). In a similar preclinical study, approxi-
ately 95% of zotarolimus is eluted from the stent within
5 days of implantation, although drug concentrations
ithin surrounding vascular tissue may be detected as late as
0 days after stent deployment (23). Zotarolimus-eluting
tents were available in diameters ranging from 2.5 mm to
.5 mm and in lengths from 9 mm to 30 mm. The control
ES stent (Cypher, Cordis Corporation, Miami Lakes,
lorida) was available in diameters ranging from 2.5 mm to
.5 mm and in lengths from 8 mm to 33 mm.
andomization, interventional procedure, and adjunc-
ive drug therapies. Patients were blinded to treatment
ssignment and randomized to the ZES or SES in a 3:1
ashion. Revascularization was to be performed with no
ore than 1 study stent except in instances of insufficient
esion coverage or as a “bailout” procedure for dissection or
hrombus. All lesions were pre-dilated with balloon angio-
lasty, and the protocol specified that stent length should be
to 5 mm longer than the lesion for adequate coverage.
oth the ZES and SES were expanded to achieve 10%
esidual stenosis by visual estimate in the treated segment,
ith a combination of the stent deployment balloon and, at
he operator’s discretion, subsequent post-dilatation bal-
oons. After stent implantation was optimized by angio-
raphic criteria, routine intravascular ultrasound (IVUS) of
he target lesion was performed.
Before revascularization, all patients received treatment
ith aspirin (325 mg/day) and clopidogrel (75 mg/day) for
t least 48 h, followed by dual antiplatelet therapy for a
inimum of 3 months after the procedure and indefinite
spirin therapy. In those patients not receiving at least 48 h
f dual anti-platelet therapy before the procedure, a loading
ose of clopidogrel (300 to 600 mg) was given immediately
efore or during the procedure. Unfractionated heparin was
dministered to achieve an activated clotting time250 s or
00 to 250 s if an intravenous glycoprotein IIb/IIIa inhibitor
as used. Treatment with additional device therapies (e.g.,
therectomy) was not permitted.
Clinical events were assessed during hospital stay and at
linic visits at 30 days and at 9 months after the index
rocedure. All patients were scheduled to undergo
ollow-up angiography and IVUS at 8 months or sooner if
he patient developed angina or objective evidence of target
essel ischemia.
ata management and core laboratories. All data were
ubmitted to a central data coordinating facility (Cardiovas-
ular Data Analysis Center, Harvard Clinical Research
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Zotarolimus-Eluting Stents December 19, 2006:2440–7nstitute, Harvard Medical School, Boston, Massachusetts).
oronary angiograms performed at baseline and at
ollow-up were reviewed by an independent angiographic
ore laboratory (Brigham and Women’s Angiographic Core
aboratory, Boston, Massachusetts). Standard image acqui-
ition was performed with 2 or more angiographic projec-
ions of the stenosis before and after stent placement.
ompulsory angiography was planned 240  30 days after
he procedure with identical angiographic projections.
ualitative analysis was performed with the modified Amer-
can College of Cardiology (ACC)/American Heart Associa-
ion (AHA) classification (24). Quantitative angiographic
nalysis was performed with a validated automated edge
etection algorithm (Medis CMS, Leiden, the Netherlands)
25). Frames were selected for analysis in the 2 “sharpest and
ightest” views that minimized foreshortening and vessel
verlap. The contrast-filled injection catheter was used as
he calibration source. A 5- to 10-mm segment of reference
iameter proximal and distal to the stenosis was used to
alculate the average reference vessel diameter at baseline,
fter stent implantation, and at follow-up. Similarly, IVUS
mages were examined by an independent core laboratory
Cardiovascular Core Analysis Laboratory, Stanford Uni-
ersity, Stanford, California) (26,27). Reviewers from each
ore laboratory were unaware of the type of stent implanted.
or both coronary angiograms and IVUS images, quantita-
ive analysis was performed to evaluate the in-stent region
bordered by the stent margins) as well as the in-segment
egion (in-stent region plus 5-mm margins proximal and
istal to the stent).
tudy end points and definitions. The primary end point
f in-segment late lumen loss was examined by quantitative
oronary angiography at 8-month angiographic follow-up.
ate lumen loss was defined as the difference between the
n-segment minimal lumen diameter (MLD) at the com-
letion of the stenting procedure and the in-segment MLD
easured at angiographic follow-up.
Secondary clinical safety and efficacy end points included
ajor adverse cardiac events (MACE: all-cause death,
yocardial infarction, and clinically driven target lesion
evascularization); the individual components of the com-
osite end point in-hospital, at 30 days, and at 9 months;
tent thrombosis (acute,1 day; subacute, 1 to 30 days; and
ate, 30 days); clinically driven target vessel revasculariza-
ion at 9 months; and target vessel failure (cardiovascular
eath, myocardial infarction, and clinically driven target
essel revascularization) at 9 months. Device success was
efined as a 50% diameter stenosis of the target lesion
determined by the core angiographic laboratory) with the
ssigned study stent, and procedure success was defined as
evice success and no in-hospital MACEs. Myocardial
nfarction was defined as a creatine kinase (CK) elevation
2 times above the upper limit of normal with any
ssociated elevation in the CK myocardial band or the
evelopment of new pathologic Q waves in 2 contiguous
lectrocardiographic leads. Clinically driven revasculariza- vion was identified as any repeat revascularization of the
arget lesion or target vessel associated with either:
) ischemic symptoms and/or an abnormal functional study
nd a 50% coronary stenosis by quantitative angiography;
r 2) any revascularization of a 70% diameter stenosis. All
rimary and secondary clinical end points were adjudicated
y an independent clinical events committee blinded to the
atient’s treatment assignment.
Secondary angiographic and IVUS efficacy end points
ncluded in-stent late lumen loss at 8 months, angiographic
inary restenosis (both in-stent and in-segment) at 8
onths, and percent volume obstruction assessed by IVUS
t 8 months. Development of acquired incomplete late stent
pposition at IVUS follow-up was identified according to
reviously described methods (28). Angiographic binary
estenosis was defined as a stenosis 50% of the lumen
iameter of the target lesion (determined by the core
ngiographic laboratory). Percent diameter stenosis was
efined as (1  [MLD/reference vessel diameter])  100,
nd acute gain was defined as the MLD immediately after
he procedure minus the MLD before the procedure.
estenosis patterns were characterized according to estab-
ished criteria (29).
tatistical methods. This randomized study was de-
igned to determine the equivalence (non-inferiority) of
-month in-segment late lumen loss with an equivalence
efinition (delta) such that the ZES would have a mean
n-segment late lumen loss 0.2 mm plus the control
ES in-segment late lumen loss. With a 3:1 (ZES/SES)
andomization and assuming a common SD of 0.55 mm,
sample size of 436 patients (323 ZES, 113 SES) with at
east 80% angiographic follow-up was required for the trial
o have 90% statistical power to detect a significant differ-
nce at an alpha level of 0.05. Patients were analyzed for all
rimary and secondary efficacy and safety end points on the
asis of the intent-to-treat principle. Baseline characteristics
f study patients were summarized in terms of frequencies
nd percentages for categorical variables and by means with
Ds for continuous variables. Categorical variables were
ompared by Fisher exact test. Continuous variables were
ompared by the 2-sample t test. Cumulative event-free
urvival was summarized as Kaplan-Meier estimates. A
value of 0.05 was established as the level of statistical
ignificance for all tests. All analyses were performed with
AS software (version 8.2 or higher, SAS Institute, Cary,
orth Carolina).
ESULTS
atient characteristics. Among 436 patients undergoing
lective percutaneous coronary revascularization, 323 pa-
ients were randomized to treatment with ZES and 113
atients were treated with SES. No significant differences
ere present in the baseline clinical or demographic char-
cteristics between patients randomized to receive ZES
ersus the control SES, except that fewer patients assigned
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December 19, 2006:2440–7 Zotarolimus-Eluting Stentso ZES were male (65.3% vs. 81.4%, p  0.001) (Table 1).
verall, the mean age was 61.5 years, 21.1% underwent
rior percutaneous coronary intervention, 68.8% had a
istory of smoking, and 29.4% had diabetes mellitus. Most
atients (61.2%) had single-vessel coronary disease, and
0.1% of patients had a history of prior myocardial
nfarction.
Baseline angiographic characteristics were also similar
Table 1), except for a higher frequency of moderate
omplexity lesions characterized as type B2 or C according
o the modified ACC/AHA classification (24) in the ZES
roup (67.4% vs. 56.6%, p  0.047). Overall, the mean
esion length was 14.97 mm, the average reference vessel
iameter was 2.76 mm, and most lesions (40.9%) were
ocated in the left anterior descending artery.
rocedural and in-hospital outcomes. The number,
ength, and diameter of stents implanted were similar in
atients assigned to each treatment group (Table 2). The
verage number of stents/target lesion was 1.15, with
verlapping stents in 23.6% of patients. Importantly, device
uccess was significantly higher among patients treated with
ES (98.8% vs. 94.7%, p  0.02). By intention to treat
nalysis, the reason for device failure in SES cases was an
nability to deliver the assigned study stent to the target
esion, except for 1 instance of an inadvertent protocol
xclusion, in which a patient was treated with a non-study
tent.
In-hospital major adverse events were higher among
atients randomized to SES, principally owing to a signif-
able 1. Baseline Patient Clinical and Angiographic Characterist
Zotarolimus-S
(n 
linical characteristics
Age (yrs) 61.42  10
Male gender (%) 65.3 (21
Diabetes mellitus (%) 29.7 (96
Hypertension (%) 70.7 (22
History of smoking (%) 66.5 (21
Hyperlipidemia (%) 83.5 (26
Prior myocardial infarction (%) 19.9 (64
Angina class III/IV (%) 59.3 (15
Prior percutaneous revascularization (%) 22.6 (73
Prior coronary bypass surgery (%) 5.3 (17
ngiographic characteristics
Target vessel (%)
Left anterior descending artery 41.3 (13
Left circumflex artery 23.3 (75
Right coronary artery 35.4 (11
Type B2/C lesions (%) 67.4 (21
Reference vessel diameter (mm) 2.75  0.4
Lesion length (mm) 14.98  6.2
Number of diseased vessels (%)
1 62.2 (20
2 29.1 (94
3 8.7 (28
Left ventricular ejection fraction (%) 55.66  9.1
alues expressed as number (%) or mean ( SD). Angina severity according to Cancantly higher incidence of non–Q-wave myocardial infarc- pion (0.6% with ZES vs. 3.5% with SES for both non–Q-
ave myocardial infarction and in-hospital MACE; p 
.04) (Table 2). Among patients with myocardial infarction,
CK-MB elevation 3 times the upper normal limit
ccurred in all patients except 1 ZES patient, and a CK
levation 3 times the upper normal limit occurred in only
patient, who was treated with SES. Administration of
ntravenous glycoprotein IIb/IIIa inhibitors did not differ
etween groups (44.0% with ZES vs. 44.6% with SES, p 
.91). Among patients with myocardial infarction, 2 of the
events in the SES group and none in the ZES group were
elated to sidebranch occlusion. There were no differences in
he frequency of myocardial infarction between patients
eceiving multiple and/or overlapping stents in either treat-
ent group. Procedure success was significantly higher with
ES than with SES (98.1% vs. 91.2%, p  0.002).
ngiographic and IVUS outcomes. Eight-month
ollow-up angiography was performed in 282 (87.3%) of
atients in the ZES group and 94 (83.2%) patients in the
ES group. There were no differences in baseline charac-
eristics and clinical outcomes in patients who did and those
ho did not undergo follow-up angiography. Both in-stent
ate lumen loss and in-stent binary restenosis were signifi-
antly higher after ZES versus SES therapy (Table 3). The
rimary end point, in-segment late lumen loss, was also
ignificantly higher among patients treated with ZES versus
ES (0.34 0.44 mm vs. 0.13 0.32 mm, p 0.001; p
.65 for non-inferiority), corresponding to a higher fre-
uency of in-segment binary restenosis (11.7% vs. 4.3%,
Group Sirolimus-Stent Group
(n  113) p Value
23) 61.73  11.59 (113) 0.80
) 81.4 (92/113) 0.001
28.3 (32/113) 0.81
) 74.3 (84/113) 0.54
) 75.2 (85/113) 0.10
) 86.7 (98/113) 0.46
20.7 (23/111) 0.89
) 55.9 (52/93) 0.62
16.8 (19/113) 0.23
8.0 (9/113) 0.35
0.55
) 39.8 (45/113)
28.3 (32/113)
) 31.9 (36/113)
) 56.6 (64/113) 0.05
2) 2.79  0.46 (113) 0.49
1) 14.95  7.28 (112) 0.96
0.40
) 58.4 (66/113)
30.1 (34/113)
11.5 (13/113)
7) 56.28  9.28 (110) 0.54
Cardiovascular Society classification.ics
tent
323)
.58 (3
1/323
/323)
7/321
2/319
8/321
/321)
6/263
/323)
/323)
3/322
/322)
4/322
7/322
6 (32
0 (32
1/323
/323)
/323)
1 (30 0.04) (Table 3). Although the pattern of in-stent
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Zotarolimus-Eluting Stents December 19, 2006:2440–7estenosis was most frequently focal in both ZES- and
ES-treated patients, the restenosis lesion length was sig-
ificantly greater in patients treated with ZES (12.94 mm
able 2. Procedural Angiographic Results and In-Hospital Clinic
Zotarolimus-Sten
(n  323)
rocedural characteristics
Number of stents 1.14  0.41 (3
Stent length (mm) 22.33  6.18 (3
Stent diameter (mm) 3.07  0.39 (3
Inflation pressure (atm) 13.54  2.51 (3
1 stent implanted (%) 12.0 (38/317
Minimal luminal diameter (mm)
Before procedure
In-lesion 0.92  0.41 (3
After procedure
In-stent 2.67  0.42 (3
In-segment 2.26  0.45 (3
Diameter stenosis (%)
Before procedure
In-lesion 66.79  12.41
After procedure
In-stent 4.35  9.77 (3
In-segment 19.43  9.23 (3
Device success (%) 98.8 (318/32
Procedural success (%) 98.1 (316/32
n-hospital outcomes
Death (%) 0 (0/323)
Myocardial infarction (%) 0.6 (2/323)
Q-wave (%) 0 (0/323)
Non–Q-wave (%) 0.6 (2/323)
Stent thrombosis (%) 0 (0/323)
Target lesion revascularization (%) 0 (0/323)
Target vessel revascularization (%) 0 (0/323)
Major adverse cardiac events (%) 0.6 (2/323)
alues expressed as number (%) or mean ( SD).
Table 3. Angiographic and IVUS Outcomes a
Zotarolimus
(n 
Quantitative angiography
Late lumen loss (mm)
In-stent 0.60 
In-segment 0.34 
Minimal luminal diameter (mm)
In-stent 2.08 
In-segment 1.92 
Diameter stenosis (%)
In-stent 24.31 
In-segment 29.88 
Binary restenosis (%)
In-stent 9.2 (
In-segment 11.7 (
Proximal margin 1.5 (
Distal margin 1.4 (
IVUS outcomes
Volume obstruction (%) 16.1 
Incomplete stent apposition (%)
Baseline 12.6 (
Persistent 6.8 (
Resolved 5.8 (
Acquired 0.5 (IVUS  intravascular ultrasound.ith ZES vs. 6.46 mm with SES, p  0.001). There were
o differences in restenosis within the proximal or distal
argins of the stents comparing ZES versus SES patients.
ents
up Sirolimus-Stent Group
(n  113) p Value
1.19  0.46 (111) 0.28
23.02  7.69 (112) 0.40
3.11  0.35 (107) 0.31
14.52  2.89 (110) 0.01
16.2 (18/111) 0.26
0.90  0.39 (113) 0.60
2.67  0.40 (112) 1.00
2.28  0.47 (113) 0.82
67.91  12.42 (113) 0.41
5.92  9.07 (112) 0.14
20.17  11.74 (113) 0.55
94.7 (107/113) 0.02
91.2 (103/113) 0.002
0 (0/113) —
3.5 (4/113) 0.04
0 (0/113) —
3.5 (4/113) 0.04
0 (0/113) —
0 (0/113) —
0 (0/113) —
3.5 (4/113) 0.04
ht Months
t Group
)
Sirolimus-Stent Group
(n  113) p Value
281) 0.15  0.34 (94) 0.001
281) 0.13  0.32 (94) 0.001
282) 2.52  0.56 (94) 0.001
282) 2.16  0.50 (94) 0.001
(282) 10.98  15.88 (94) 0.001
(282) 23.86  13.87 (94) 0.001
2) 2.1 (2/94) 0.02
2) 4.3 (4/94) 0.04
) 1.1 (1/87) 1.0
) 1.1 (1/92) 1.0
185) 2.7  3.1 (61) 0.001
7) 17.9 (17/95) 0.22
0) 11.8 (8/68) 0.21
0) 7.4 (5/68) 0.77
) 5.9 (4/68) 0.02al Ev
t Gro
17)
22)
16)
18)
)
22)
22)
22)
(322)
22)
22)
2)
2)t Eig
-Sten
323
0.48 (
0.44 (
0.57 (
0.52 (
17.08
15.27
26/28
33/28
4/270
4/281
10.8 (
31/24
13/19
11/19
1/190
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December 19, 2006:2440–7 Zotarolimus-Eluting StentsImmediate post-procedural IVUS measurements did not
iffer significantly among the 2 study groups. Follow-up
VUS at 8 months (with images suitable for analysis) was
erformed in 187 (59.2%) patients in the ZES group and 61
54.0%) patients in the SES group. At 8 months, percent
olume obstruction (16.1  11% vs. 2.7  3%, p  0.001)
as significantly greater with ZES compared with SES
Table 3). Importantly, newly observed incomplete late
tent apposition with abnormal remodeling and vessel ex-
ansion occurred in 4 patients (5.9%) treated with SES and
n only 1 (0.5%) patient receiving ZES (p 0.02) (Table 3).
ine-month clinical outcomes. Clinical follow-up was
ompleted in 316 patients (97.8%) in the ZES group and in
13 patients (100%) in the SES group (Table 4). There
ere no episodes of acute, subacute, or late stent thrombosis
n either treatment group. There were 2 (0.6%) deaths in the
ES group and none in the SES group. The deaths in the
ES group were due to stroke in 1 patient and pancreatic
ancer in the other patient. There were no out-of-hospital
yocardial infarctions in either group, such that the early
ower frequency of myocardial infarctions with ZES per-
isted during the follow-up period. The occurrence of
linically driven target lesion revascularization did not sig-
ificantly vary between the ZES and SES groups (6.3%
ES vs. 3.5% SES, p  0.34) (Table 4). Target vessel
evascularization unrelated to the target lesion was also
imilar between ZES and SES groups (6.0% with ZES vs.
.3% with SES, p  1.0). Target lesion revascularization
djudicated as non-clinically driven (i.e., occurring without
n abnormal functional study or70% stenosis) occurred in
n additional 11 (3.5%) patients treated with ZES; there-
ore, the total (clinically and non-clinically driven) target
esion revascularization rates were 9.8% and 3.5% for the
ES and SES groups, respectively (p  0.04). There were
o significant differences between ZES and SES in the
ccurrence of MACEs (7.6% vs. 7.1%, p  1.0) and target
essel failure (12.0% vs. 11.5%, p  1.0). Actuarial event-
able 4. Clinical Events at Nine Months
Zotarolimus-Stent Gr
(n  323)
eath (%) 0.6 (2/316)
yocardial infarction (%) 0.6 (2/316)
Q-wave (%) 0 (0/316)
Non–Q-wave (%) 0.6 (2/316)
tent thrombosis (%) 0 (0/316)
arget lesion revascularization (%) 6.3 (20/316)
Percutaneous 5.4 (17/316)
Surgical 0.9 (3/316)
arget vessel revascularization—not involving
target lesion (%)
6.0 (19/316)
Percutaneous 5.7 (18/316)
Surgical 0.3 (1/316)
ajor adverse cardiac events (%) 7.6 (24/316)
arget vessel failure (%) 12.0 (38/316)ree survival at 9 months for clinically driven target lesion
M
ievascularization, MACEs, and target vessel failure did not
ignificantly differ among ZES and SES patients (Fig. 1).
ISCUSSION
n this prospective, randomized trial comparing the clinical
fficacy, safety, and angiographic outcomes among patients
reated with ZES and SES, treatment with ZES was
ssociated with increased neointimal hyperplasia resulting in
reater angiographic late lumen loss.
The reasons for higher late lumen loss observed with ZES
n this trial compared with SES (the primary end point) and
ther studies are incompletely understood. Among patients
reated with ZES in the first-in-man ENDEAVOR I
100-patient) and large (1,200-patient), randomized
NDEAVOR II trials (8,30), for example, angiographic
easurement of in-stent late lumen loss was 0.61 mm in
oth studies, compared with 0.60 mm in the current study.
ncreased neointimal hyperplasia with ZES might be due to
ifferences in biological activity of zotarolimus compared
ith sirolimus, although in vitro cell culture experiments
nd animal studies would suggest equivalent nanomolar
otencies in suppressing smooth muscle cell proliferation (23).
Sirolimus-Stent Group
(n  113) p Value
Relative Risk
[95% Confidence Interval]
0 (0/113) 1.0 —
3.5 (4/113) 0.04 0.18 [0.03, 0.96]
0 (0/113) — —
3.5 (4/113) 0.04 0.18 [0.03, 0.96]
0 (0/113) — —
3.5 (4/113) 0.34 1.79 [0.62, 5.12]
3.5 (4/113) 0.61 1.52 [0.52, 4.42]
0 (0/113) 0.57 —
5.3 (6/113) 1.0 1.13 [0.46, 2.76]
5.3 (6/113) 1.0 1.07 [0.44, 2.63]
0 (0/113) 1.0 —
7.1 (8/113) 1.0 1.07 [0.50, 2.32]
11.5 (13/113) 1.0 1.05 [0.58, 1.89]
igure 1. Kaplan-Meier event-free survival to 9 months for patients
reated with zotarolimus- (ZES) and sirolimus-eluting (SES) stents.oupACE  major adverse cardiac events; TLR  target lesion revascular-
zation; TVF  target vessel failure.
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Zotarolimus-Eluting Stents December 19, 2006:2440–7nother potential reason for the observed differences is that
he more rapid elution kinetics of zotarolimus from the
hosphorylcholine polymer—95% eluted in approximately 2
eeks (23)—compared with the slower release of sirolimus
rom the polyethylene-co-vinyl acetate/poly n-butyl
ethacrylate co-polymer—95% eluted in approximately 6
eeks—might significantly influence biological efficacy.
ptimal suppression of procedural-induced injury responses
esulting in inflammation and subsequent intimal hyperpla-
ia might require more prolonged tissue exposure to the
herapeutic agent. Lastly, there might be differences in
iological responses to either the stent or the phosphoryl-
holine polymer itself.
Regarding secondary end points, the results from this trial
re the first among comparative drug-eluting stent trials to
emonstrate a statistically significant difference in both
rocedural device success and in-hospital clinical outcome.
irst, device success was significantly higher with ZES,
wing to enhanced stent deliverability likely associated with
more flexible, low profile thin-strut cobalt alloy stent.
econd, although infrequent in both groups, the occurrence
f in-hospital non–Q-wave myocardial infarctions was
ignificantly lower with ZES compared with SES. This
bservation is more difficult to reconcile, given that most
rocedural, demographic, and baseline angiographic char-
cteristics did not differ between the 2 groups.
Although the angiographic and IVUS follow-up analyses
avored SES compared with ZES, differences in clinical
utcome were less consistent. Most clinical end points did
ot statistically differ between these 2 drug-eluting stents
Table 4), including clinically driven target lesion revascu-
arization (6.3% for ZES vs. 3.5% for SES, p  0.34).
owever, overall target lesion revascularization (clinically
nd non-clinically driven) was significantly more common
n the ZES group. The modest but statistically significant
enefit associated with lower peri-procedural myocardial
nfarction rates with ZES was offset by the slightly higher
igure 2. Logistic regression relationship between late lumen loss and targ
tents.ollow-up target lesion revascularization frequencies, such ihat the composite target vessel failure and MACE values
or ZES and SES were similar. As with previous studies
sing paclitaxel-eluting stents (3,6,7), a discordance might
xist between angiographic and clinical outcomes in this
ES trial, suggesting that there might be an angiographic
ate lumen loss threshold or “window” below which the
ccurrence of repeat clinically driven revascularization
vents is unlikely (Fig. 2). In low- or medium-complexity
esions, an in-stent late loss of 0.60 mm and an in-segment
ate loss of 0.34 mm were in most instances well tolerated
nd not sufficient to induce important changes in clinically
riven target lesion revascularization compared with SES.
f course, in higher complexity lesions (such as diffuse
isease, in-stent restenosis, or small vessels), where there is
he potential for an upward drift in late lumen loss, greater
ifferences between ZES and SES might become apparent.
t present, an international “open” registry with ZES is
ngoing to provide insights regarding the clinical efficacy of
ES in a broad, unselected patient population with greater
esion complexity and in varied clinical settings.
tudy limitations. There are several limitations of this
tudy. Because the primary objective of the study was to
ompare an angiographic surrogate end point—follow-up
n-segment late lumen loss—between 2 drug-eluting stents,
he sample size did not enable adequate statistical power to
igorously examine differences among pertinent clinical end
oints. Moreover, the unbalanced randomization resulted in
very small SES comparison group, such that results for
ES were subject to potential over-interpretation due to
road confidence intervals. It is also noteworthy that the
ifferences between ZES and SES were somewhat exagger-
ted in this clinical trial, owing to an unexpectedly low SES
n-segment late lumen loss compared with other recent SES
linical trials (1,2,17). Unlike previous double-blinded drug-
luting stent versus bare metal stent clinical trials, this study
as single-blinded, and the identity of the treatment stent
as known to the interventional operator, which could
ion revascularization (TLR) for patients treated with zotarolimus-elutingntroduce bias in procedural outcomes and the performance
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December 19, 2006:2440–7 Zotarolimus-Eluting Stentsf repeat revascularization. As stated, the results from this
rial are specific to the patient population studied and
annot be generalized to the much broader population of
atients with more complex lesion morphologies.
onclusions. As demonstrated in this ZES versus SES
linical trial, ZES was shown to have significantly higher
ngiographic late lumen loss. Although most other angio-
raphic outcomes favored SES, differences in secondary
linical end points were not consistent between the 2 stent
roups. Clinical interventional operators will have to con-
ider the overall attributes of ZES versus SES in making
ecisions concerning preferential device use under specific
linical circumstances.
eprint requests and correspondence: Dr. David E. Kandzari,
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